Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apyx Medical Co. stock logo
APYX
Apyx Medical
$1.45
-2.0%
$1.68
$1.21
$7.97
$50.23M1.09143,422 shs58,356 shs
Liquidia Co. stock logo
LQDA
Liquidia
$12.53
+1.3%
$14.55
$5.71
$16.99
$952.66M0.16947,755 shs526,539 shs
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$7.19
+7.5%
$8.74
$3.78
$13.62
$397.03M1.67179,437 shs71,083 shs
Soliton, Inc. stock logo
SOLY
Soliton
$22.58
$21.55
$7.40
$22.60
$487.66M0.19347,827 shsN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
$0.68
-11.0%
$0.81
$0.60
$4.70
$4.35M0.66442,281 shs21,983 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apyx Medical Co. stock logo
APYX
Apyx Medical
-1.33%+7.25%+15.63%-34.80%-49.66%
Liquidia Co. stock logo
LQDA
Liquidia
-1.43%-10.43%-22.30%+1.64%+82.99%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-2.48%-9.10%-18.91%-21.48%+14.75%
Soliton, Inc. stock logo
SOLY
Soliton
0.00%0.00%0.00%0.00%0.00%
Venus Concept Inc. stock logo
VERO
Venus Concept
+6.66%-8.46%+9.05%-37.99%-73.56%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apyx Medical Co. stock logo
APYX
Apyx Medical
4.3552 of 5 stars
3.55.00.04.21.81.70.6
Liquidia Co. stock logo
LQDA
Liquidia
2.2453 of 5 stars
3.31.00.00.02.14.20.6
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/AN/AN/AN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
2.0266 of 5 stars
0.05.00.00.02.93.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apyx Medical Co. stock logo
APYX
Apyx Medical
3.00
Buy$6.17325.29% Upside
Liquidia Co. stock logo
LQDA
Liquidia
2.60
Moderate Buy$21.0067.60% Upside
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/A
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
2.00
HoldN/AN/A

Current Analyst Ratings

Latest LQDA, PLSE, APYX, VERO, and SOLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
4/1/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
3/14/2024
Liquidia Co. stock logo
LQDA
Liquidia
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $32.00
3/13/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
2/21/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apyx Medical Co. stock logo
APYX
Apyx Medical
$52.35M0.96N/AN/A$0.78 per share1.86
Liquidia Co. stock logo
LQDA
Liquidia
$17.49M54.47N/AN/A$0.73 per share17.16
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$700K567.19N/AN/A$0.81 per share8.88
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/A$1.46 per shareN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
$76.35M0.06N/AN/A($2.43) per share-0.28

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$18.71M-$0.54N/AN/AN/A-35.75%-54.90%-28.41%5/9/2024 (Confirmed)
Liquidia Co. stock logo
LQDA
Liquidia
-$78.50M-$1.20N/AN/AN/A-448.89%-132.16%-65.35%5/2/2024 (Estimated)
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-$42.21M-$0.89N/AN/AN/A-112.74%-61.09%5/7/2024 (Confirmed)
Soliton, Inc. stock logo
SOLY
Soliton
-$14.54M-$1.01N/AN/AN/AN/A-71.85%-62.92%N/A
Venus Concept Inc. stock logo
VERO
Venus Concept
-$37.25M-$6.85N/AN/AN/A-48.79%N/A-36.21%5/15/2024 (Confirmed)

Latest LQDA, PLSE, APYX, VERO, and SOLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2024N/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/AN/A  
5/9/2024N/A
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$0.18N/A+$0.18N/AN/AN/A  
5/7/2024N/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/AN/A  
4/1/2024Q4 2023
Venus Concept Inc. stock logo
VERO
Venus Concept
N/A-$2.01-$2.01-$2.01N/A$18.13 million
3/28/2024Q4 2023
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A-$0.21-$0.21-$0.20N/AN/A
3/21/2024Q4 2023
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$0.13-$0.19-$0.06-$0.10$14.40 million$14.66 million
3/13/2024Q4 2023
Liquidia Co. stock logo
LQDA
Liquidia
-$0.23-$0.42-$0.19-$0.42$5.29 million$4.53 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apyx Medical Co. stock logo
APYX
Apyx Medical
N/AN/AN/AN/AN/A
Liquidia Co. stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/A
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apyx Medical Co. stock logo
APYX
Apyx Medical
1.23
5.52
4.74
Liquidia Co. stock logo
LQDA
Liquidia
N/A
4.85
4.85
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A
6.76
6.76
Soliton, Inc. stock logo
SOLY
Soliton
N/A
5.47
5.37
Venus Concept Inc. stock logo
VERO
Venus Concept
N/A
2.13
1.39

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
55.33%
Liquidia Co. stock logo
LQDA
Liquidia
64.54%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
76.95%
Soliton, Inc. stock logo
SOLY
Soliton
35.11%
Venus Concept Inc. stock logo
VERO
Venus Concept
87.41%

Insider Ownership

CompanyInsider Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
13.10%
Liquidia Co. stock logo
LQDA
Liquidia
31.60%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
69.70%
Soliton, Inc. stock logo
SOLY
Soliton
12.00%
Venus Concept Inc. stock logo
VERO
Venus Concept
51.39%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Apyx Medical Co. stock logo
APYX
Apyx Medical
25234.64 million30.11 millionOptionable
Liquidia Co. stock logo
LQDA
Liquidia
14576.03 million52.00 millionOptionable
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
6155.22 million16.73 millionOptionable
Soliton, Inc. stock logo
SOLY
Soliton
1421.60 million19.01 millionNot Optionable
Venus Concept Inc. stock logo
VERO
Venus Concept
3046.36 million3.09 millionNot Optionable

LQDA, PLSE, APYX, VERO, and SOLY Headlines

SourceHeadline
Venus Concept Announces Loan Purchase and Completion of First Phase of RefinancingVenus Concept Announces Loan Purchase and Completion of First Phase of Refinancing
finance.yahoo.com - April 24 at 7:48 PM
Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024
globenewswire.com - April 15 at 7:30 AM
Venus Concept Inc.: Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAXVenus Concept Inc.: Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
finanznachrichten.de - April 9 at 1:29 AM
Venus Concept Announces Approval For Venus Bliss MAX In Israel - Quick FactsVenus Concept Announces Approval For Venus Bliss MAX In Israel - Quick Facts
markets.businessinsider.com - April 8 at 10:21 AM
Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAXVenus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
globenewswire.com - April 8 at 7:30 AM
Ranking every single MoonSwatch thats ever droppedRanking every single MoonSwatch that's ever dropped
gq-magazine.co.uk - April 3 at 10:37 PM
On heels on Vero Beach, Sebastian growth, Fellsmere population to double in five years?On heels on Vero Beach, Sebastian growth, Fellsmere population to double in five years?
news.yahoo.com - April 3 at 10:37 PM
Venus Concept Announces Australian Regulatory Approval for Venus Versa ProVenus Concept Announces Australian Regulatory Approval for Venus Versa Pro
finance.yahoo.com - April 3 at 7:36 AM
Venus Concept Announces Australian Regulatory Approval for Venus Versa ProVenus Concept Announces Australian Regulatory Approval for Venus Versa Pro
globenewswire.com - April 3 at 7:30 AM
Venus Concept Inc.: Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsVenus Concept Inc.: Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
finanznachrichten.de - April 2 at 9:35 PM
VERO Stock Earnings: Venus Concept Misses EPS, Misses Revenue for Q4 2023VERO Stock Earnings: Venus Concept Misses EPS, Misses Revenue for Q4 2023
investorplace.com - April 1 at 1:03 PM
Venus Concept: Q4 Earnings SnapshotVenus Concept: Q4 Earnings Snapshot
houstonchronicle.com - April 1 at 9:42 AM
Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsVenus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
globenewswire.com - April 1 at 7:00 AM
Venus Concept Inc.: Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing RulesVenus Concept Inc.: Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
finanznachrichten.de - March 26 at 2:33 AM
Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing RulesVenus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
globenewswire.com - March 25 at 7:30 AM
Venus Concept Launches "NEXThetics" ProgramVenus Concept Launches "NEXThetics" Program
stockhouse.com - March 13 at 10:30 AM
Venus Concept Launches “NEXThetics” ProgramVenus Concept Launches “NEXThetics” Program
globenewswire.com - March 12 at 4:05 PM
Venus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesVenus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
globenewswire.com - February 27 at 4:05 PM
Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesVenus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
globenewswire.com - February 23 at 8:00 AM
Nasdaq Surges 300 Points; NVIDIA Posts Strong ResultsNasdaq Surges 300 Points; NVIDIA Posts Strong Results
msn.com - February 23 at 1:09 AM
Venus Concept Announces CE Mark for Venus Versa Pro in EuropeVenus Concept Announces CE Mark for Venus Versa Pro in Europe
finance.yahoo.com - February 22 at 10:08 AM
Venus Concept Announces CE Mark for Venus Versa Pro in EuropeVenus Concept Announces CE Mark for Venus Versa Pro in Europe
globenewswire.com - February 22 at 7:30 AM
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
finance.yahoo.com - February 20 at 10:42 AM
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
globenewswire.com - February 20 at 7:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Apyx Medical logo

Apyx Medical

NASDAQ:APYX
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally. It operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). The company offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. Its Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also develops and manufactures hand pieces for open and laparoscopic procedures; and OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Liquidia logo

Liquidia

NASDAQ:LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Pulse Biosciences logo

Pulse Biosciences

NASDAQ:PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Soliton logo

Soliton

NASDAQ:SOLY
Soliton, Inc. is a medical development company, which engages in the development of healthcare technological devices for medical and cosmetic treatments. Its technology platform include Rapid Acoustic Pulse, a device uses rapid pulses of designed acoustic shockwaves to disrupt cellular structures in the dermal and subdermal tissue. The firm is also in the pre-revenue stage with its first products being developed for the removal of tattoos and the reduction of cellulite. The company was founded by Walter V. Klemp and Christopher Capelli on March 27, 2012 and is headquartered in Houston, TX.
Venus Concept logo

Venus Concept

NASDAQ:VERO
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.